Numerous case reports and studies have suggested a link between antipsychotic medication use and diabetes mellitus, impaired glucose tolerance, and insulin resistance in adult populations, although the evidence has been inconsistent, particularly with regard to the different effects of specific agents.
The use of second-generation antipsychotics (SGAs) has increased dramatically for children and adolescents, [1] [2] [3] [4] [5] although the majority of use in this population is off-label and data on safety and efficacy are limited. Data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey indicate that antipsychotic prescribing increased from 8.6 visits per 1000 US children (2-18 years of age) in 1995-1996 to 39.4 visits per 1000 US children in [2001] [2002] . 2 Studies indicate increased use among very young children (2-5 years of age) 6 and use of SGAs in combination with other drugs. 7 In addition, studies reported that 15% of antipsychotic users in the noninstitutionalized US population were children 4 and that almost one-fourth of users in a Medicaid population were children. 8 Numerous case reports and studies have suggested a link between the use of antipsychotic medications and diabetes mellitus, impaired glucose tolerance, and insulin resistance in adult populations, although the evidence has been inconsistent, particularly with respect to the different effects of specific agents. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Furthermore, although studies indicated rapid effects on weight gain, fat mass, and waist circumference in children, [20] [21] [22] evidence suggesting an association between impaired glucose tolerance and antipsychotic use in children is limited. 8, 20, 23 Given the clinical complications (cardiovascular, neurologic, and renal) associated with diabetes, the clinical and public health implications of any increased risk in the pediatric population with these agents are large. The objective of the present study was to evaluate the risk of incident diabetes mellitus associated with the use of SGAs in a large diverse cohort of children treated in typical clinical practice.
METHODS

Study Population
A retrospective cohort study was conducted by using the administrative databases of 3 Health Maintenance Organization Research Network health plans from [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] . The health plans enroll Ͼ700 000 youths 5 to 18 years of age. Health plan providers are allowed to prescribe both formulary and nonformulary SGAs, although the cost for the patient may be higher for a nonformulary agent; the relative rates of use of specific agents at the 3 sites were similar during the observation period. For each health plan, children and adolescents 5 to 18 years of age who filled a prescription for a SGA between January 1, 2001, and December 31, 2008, were identified by using automated pharmacy dispensing records. All medications were identified through National Drug Codes. New users of SGAs were identified by selecting members whose initial dispensing was preceded by Ն1 year of continuous enrollment with drug benefits and no dispensing of a SGA in the previous 6 months. Two comparison groups were identified. Comparison group 1 included youths 5 to 18 years of age who did not receive any psychotropic drugs during the observation period, who were matched individually 4:1 with subjects who were exposed to antipsychotic medications, with respect to age, gender, and enrollment (health plan membership on the date of initial dispensing of the antipsychotic drug and Ն1 year previously). Comparison group 2 included youths 5 to 18 years of age who were new users of selective serotonin reuptake inhibitors or tricyclic antidepressants. Identical membership and benefits requirements were applied to the comparison groups.
Children with known preexisting diabetes mellitus were excluded from the study. Preexisting diabetes was identified by using administrative databases to identify patients with a diagnosis code for diabetes mellitus (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 250.00 -250.9X) or dispensing of an antidiabetic medication during the 12 months before the initial antipsychotic dispensing date or the start of the follow-up period for the exposed and comparison groups. Exposed person-time was determined from the dispensing dates and the days of supply dispensed, as documented in the automated pharmacy records. A person's medication exposure started on the initial date a SGA (or antidepressant) was dispensed and extended until the earliest of (1) the occurrence of new-onset diabetes mellitus, (2) 1 year after the initiation of medication therapy, (3) the end of the study period (December 31, 2008), (4) health plan disenrollment, (5) a switch to another psychotropic therapy, as indicated by pharmacy records, or (6) discontinuation of therapy, calculated as 30 days after exhaustion of the estimated supply for successive prescriptions for the drug, as indicated by pharmacy records. Gaps of Ͻ30 days between the expected and actual refill dates for successive prescriptions (on the basis of supply dispensed) were counted as continuously exposed days. For patients included in the comparison group of nonusers of psychotropic drugs, exposed person-time started on the matched exposed patient's initial dispensing date (index date) and extended until the earliest of (1) the occurrence of new-onset diabetes mellitus, (2) 1 year after the index date, (3) the end of the study period, or (4) health plan disenrollment. These end points were chosen because the majority of newly diagnosed cases of diabetes among children and adolescents taking SGAs are reported to occur within 6 months after initiation of therapy 24, 25 and the majority of children in our study were exposed to SGAs for Ͻ1 year.
Main Outcome Measures
We used the computerized health plan databases to identify potential cases of diagnosed and/or treated diabetes mellitus. The specific criteria included (1) an inpatient or outpatient diagnosis code for diabetes mellitus (ICD-9-CM codes 250.00 -250.9X), (2) dispensing of an antidiabetic medication (single or combination formulations, including insulin preparations, pioglitazone, rosiglitazone, troglitazone, metformin, chlorpropamide, glipizide, glimepiride, glyburide, tolazamide, tolbutamide, saxagliptin, sitagliptin, exenatide, miglitol, acarbose, nateglinide, pramlintide, and repaglinide), or (3) a laboratory test result of a hemoglobin A1c level of Ն7%, a fasting plasma glucose level of Ն126 mg/dL, or a casual plasma glucose level of Ն200 mg/dL.
Our primary definition for the outcome of interest was a diagnosis code for diabetes mellitus or dispensing of an antidiabetic medication (criteria 1 and/or 2 described above). Female members Ն12 years of age who received metformin only were not included in this definition. We also expanded our definition of diabetes to include an abnormal glucose laboratory test result (criteria 1, 2, and/or 3), to test in secondary analyses whether the association of incident diabetes with SGA exposure might be sensitive to the definition of diabetes.
Demographic and Clinical Characteristics of Patients
Health plan administrative databases were used to obtain information on potential confounders, including age, gender, mental health and developmental conditions (schizophrenic dis- 
Analyses
Incidence rates for new-onset diabetes mellitus were estimated for children and adolescents by using 2 case definitions that were based on the criteria described above. Incidence rates were calculated with 95% confidence intervals (CIs) according to the Poisson distribution. Multivariate Poisson regression was used to estimate the strength of association between SGA use (versus nonuse) and new-onset diabetes mellitus, and separate analyses were performed for the 2 comparison groups and adjustment for potential confounders. Stata 11 (Stata Corp, College Station, TX) was used to fit exact Poisson regression models.
We also performed a secondary analysis matching the SGA users to each of the 2 comparison groups by using propensity score methods. Propensity score matching is considered an alternative to multivariate modeling. 26 By using data for subjects exposed and not exposed (in this case, exposure is SGA use), a model is built to predict exposure by using covariates (and not the outcome). By using the probability of exposure (propensity for exposure), individuals in the unexposed group are matched to subjects in the exposed group, so that a comparison of outcomes is made between groups with similar propensities for exposure. We estimated the probability of receiving a SGA by using logistic regression with the following variables: age, gender, mental health and developmental conditions (schizophrenia, mood disorders, autism, and disruptive behavioral disorders) within 6 months of initiation of therapy or follow-up monitoring, oral corticosteroid use in the previous 3 months, frequency of ambulatory care visits in the previous 6 months, calendar year of initiation of therapy, use of other psychotropic medications (antianxiety medications or mood stabilizers), and use of drugs to treat attention-deficit/hyperactivity disorder in the previous 6 months. Because children in comparison group 1 (who did not receive any psychotropic drugs) were individually matched to individuals who were exposed to antipsychotic medications, with respect to age, gender, and enrollment on the date of initial dispensing of the antipsychotic drug, these variables were not evaluated in the logistic regression models used to estimate the propensity scores. Diagnostic measures for the propensity score models showed adequate ability to distinguish SGA users from nonusers of psychotropic drugs and antidepressant users (c statistics of 0.95 and 0.78, respectively). 27 From these models, we generated propensity scores, which were used to match SGA users to each of the 2 comparison groups by using a 1:1 nearestneighbor method without replacements. The closest comparison subject whose propensity score differed by Ͻ0.01 was selected, and unmatched individuals were not included. The study was approved by the institutional review board of each participating organization.
RESULTS
A total of 9636 children and adolescents initiated SGA medication therapy and met eligibility criteria. Approximately 60% of SGA users were male, and 46% were between the ages of 15 and 18 years. Table 1 lists characteristics of the children exposed to SGAs and the 2 comparison groups.
A total of 57 children were identified as having incident diabetes, by using our primary criteria, during the follow-up period. For children with incident diabetes who received a SGA, average daily dosages were within recommended ranges. Among the children with incident diabetes, the mean times to diagnosis were 138 days (SD: 90 days) for users of SGAs (n ϭ 12), 173 days (SD: 117 days) for children who did not receive psychotropic medications (n ϭ 26), and 143 days (SD: 119 days) for users of antidepressants (n ϭ 19). The crude incidence rate of diabetes for the SGA-exposed cohort was 3.23 cases per 1000 person-years (95% CI: 1.67-5.65), compared with 0.76 cases per 1000 person-years (95% CI: 0.49 -1.12) for the no-psychotropic medication use cohort and 1.86 cases per 1000 person-years (95% CI: 1.12-2.90) for the antidepressant-exposed cohort (Table 2 ). For the combined population of children exposed to SGAs and children exposed to antidepressants, no statistically significant association was found for diabetes and any characteristic (demographic, health care utilization, or clinical or mental health) evaluated.
In the propensity score matching, 2531 children in the SGA-exposed group (26%) were matched to children in comparison group 1 (no psychotropic use) and 8012 (83%) were matched to children in comparison group 2 (antidepressant use). Even after the matching, there were statistically significant differences between the groups in a number of characteristics, although , and autism (3% of SGA users were diagnosed as having autism, compared with 2% in the comparison group). The SGA and antidepressant groups were more similar after matching, and there were slight differences in mental health diagnoses (with absolute differences between the groups of Յ2 percentage points). In total, there were 3 incident cases of diabetes in the matched SGA and no-psychotropic medication groups and 13 incident cases of diabetes in the matched SGA and antidepressant groups. The IRRs for the association between diabetes and SGA use were 4.47 (95% CI: 0.23-263.82) for comparison group 1 (no psychotropic use) and 3.58 (95% CI: 0.92-20.30) for comparison group 2 (antidepressant use) (Table 3) .
A total of 104 children exhibited the secondary outcome of a diagnosis of diabetes mellitus, dispensing of an antidiabetic medication, or an abnormal glucose laboratory test result during the follow-up period. Unadjusted and multivariate analyses suggested similar associations between this secondary outcome and SGA exposure as were observed for the primary outcome ( 
DISCUSSION
We conducted a retrospective cohort study that included Ͼ9000 children and adolescents who initiated therapy with SGAs, to investigate a possible association between SGA use and the risk of diabetes mellitus. Estimates of the effect of SGA use were determined with 2 separate comparison groups. The findings differed depending on the comparison group and the definition of the outcome of interest. We found an increased incidence of diabetes among children within the first year after initiation of SGA therapy, compared with children who were not using any psychotropic medications. This finding persisted when the incidences of both diabetes and abnormal glucose laboratory values were evaluated. We found no statistically significant difference in the risk of diabetes among children initiating SGA therapy, compared with those initiating antidepressant therapy; however, the IRR estimate after propensity score matching was of marginal significance.
Different effects of specific SGA medications on weight gain and insulin resistance have been suggested to influence the risk for diabetes mellitus. 28, 29 Clozapine and olanzapine seem to have the highest risk of weight gain, followed by quetiapine. 30, 31 Possible mechanisms include antagonism of serotonin 5-HT 1A/2A/2C receptors, resulting in inhibition of insulin release, insulin resistance, or impairment of glucose utilization. [31] [32] [33] Effects of the SGAs on ␣ 2 -adrenergic receptors also may influence pancreatic ␤-cell function. 31 Previous evidence suggested that youths receiving SGAs experience adverse changes in body composition and metabolic parameters even after short-term therapy. The nonrandomized Second-Generation Antipsychotic Treatment Indications, Effectiveness, and Tolerability in Youth study found significant increases in body composition parameters such as weight, fat mass, and BMI for all antipsychotic medications assessed (aripiprazole, olanzapine, quetiapine, and risperidone) after a median of 10.8 weeks of treatment, compared with an untreated comparison group; patients receiving olanzapine experienced the highest incidence rates of hyperglycemia and metabolic syndrome. 20 A retrospective study that used Medicaid claims data reported higher rates of either diagnosis of a glucose disturbance or antidiabetic medication dispensing within 6 months after initiation of therapy among children receiving SGAs, compared with a group of children receiving albuterol. 8 Evaluations of case series of spontaneous reports to the US Food and Drug Administration MedWatch drug surveillance system indicated that the majority of newly diagnosed cases and exacerbations of preexisting diabetes among children and adolescents receiving SGAs were reported within 6 months after initiation of therapy. 24, 25 The choice of an appropriate comparison group is crucial to an understanding of the association between SGA use and diabetes, because of confounding according to indication and potential detection bias. Therefore, in addition to evaluating the association by using a comparison group of children not ex- a Propensity scores were generated and were used to match SGA users to each of the 2 comparison groups by using a 1:1 nearest-neighbor method without replacements; 2531 children in the SGA-exposed group (26%) were matched to children in comparison group 1 (no psychotropic medication use), and 8012 (83%) were matched to children in comparison group 2 (antidepressant use).
posed to psychotropic medications, we evaluated the association by using a group of children exposed to antidepressant medications. This approach allowed us to select children more likely to be similar to SGA users in terms of treatment for mental health conditions and the potential for detection/diagnosis of diabetes. Recent published studies reported an association between antidepressant use and the risk of diabetes, particularly among long-term users of antidepressants or patients receiving high doses of antidepressant medications 34, 35 ; evidence is conflicting regarding such an association. 36 If a causal association exists between antidepressant medication use and diabetes, then the use of this comparison group might have attenuated an actual association between SGA use and diabetes in the present study.
Our study evaluated the association with SGA medications in a large diverse cohort of well-characterized pediatric patients from 3 geographically distributed health plans that monitor patients for longitudinal exposures and clinical outcomes. An additional strength of our study was the ability to identify and to evaluate glucose laboratory values within this population.
One limitation of our study was the small number of cases identified, which precluded detailed evaluation of the associations between individual agents and the risk of diabetes, as well as investigation of whether the risk varied in relation to dose. In addition, only diagnosed cases of diabetes were identified; therefore, cases of diabetes might have been undetected in our study population. It was not possible to differentiate type 1 from type 2 diabetes mellitus by using administrative data. The potential pathophysiologic effects of SGA use would be expected to increase the risk of only type 2 diabetes. The likely effect of this misclassification would be that our IRR estimate was biased toward the null. Finally, residual confounding was possible, because we did not evaluate potential confounders such as baseline BMI, diet, exercise, race/ethnicity, severity of underlying mental health conditions, or long-term use. We performed secondary analyses by using propensity score methods to adjust for potential confounding; however, estimates of the association were imprecise because of the low matching rates.
CONCLUSIONS
We found a potentially fourfold increased rate of diabetes among children exposed to SGAs in comparison with children not exposed but no statistically significantly increased rate in comparison with children exposed to antidepressant medications. Given the clinical complications associated with diabetes, the potentially increased risk of diabetes with these agents in the pediatric population is an important drug safety and public health issue.
Limitations of the present study, including the small number of cases, suggest that additional research is needed to define the nature and magnitude of the diabetes risk associated with SGA use among children.
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